Bulletin
Investor Alert

New York Markets Open in:

Seattle Genetics Inc.

NAS: SGEN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Dec 13, 2019, 5:10 p.m.

/zigman2/quotes/203326163/composite

$

113.87

Change

0.00 0.00%

Volume

Volume 100,099

Quotes are delayed by 20 min

/zigman2/quotes/203326163/composite

Previous close

$ 112.26

$ 113.87

Change

+1.61 +1.43%

Day low

Day high

$111.68

$114.86

Open

52 week low

52 week high

$51.50

$122.36

Open

Company Description

Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for soli...

Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Valuation

P/E Current

-80.61

P/E Ratio (with extraordinary items)

-62.91

Price to Sales Ratio

13.64

Price to Book Ratio

7.13

Enterprise Value to EBITDA

-81.66

Enterprise Value to Sales

23.84

Efficiency

Revenue/Employee

502,842.00

Income Per Employee

-171,039.00

Receivables Turnover

5.67

Total Asset Turnover

0.55

Liquidity

Current Ratio

2.90

Quick Ratio

2.67

Cash Ratio

1.82

Profitability

Gross Margin

86.51

Operating Margin

-39.71

Pretax Margin

-37.63

Net Margin

-34.01

Return on Assets

-18.70

Return on Equity

-22.82

Return on Total Capital

-26.65

Return on Invested Capital

-22.82

Capital Structure

Officers and Executives

Name Age Officer Since Title
Dr. Clay B. Siegall 58 1998 Chairman, President & Chief Executive Officer
Mr. Todd E. Simpson 58 2005 Chief Financial & Accounting Officer
Dr. Roger D. Dansey - 2018 Chief Medical Officer
Dr. Vaughn B. Himes 57 2009 Chief Technical Officer
Dr. Robert J. Lechleider - 2016 Senior Vice President-Clinical Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/09/2019 Clay B. Siegall
President and CEO; Director
500   Disposition at $117.76 per share. 58,880
12/09/2019 Clay B. Siegall
President and CEO; Director
1,800   Disposition at $116.98 per share. 210,564
12/09/2019 Clay B. Siegall
President and CEO; Director
2,111   Disposition at $115.53 per share. 243,883
12/09/2019 Clay B. Siegall
President and CEO; Director
6,734   Disposition at $114.59 per share. 771,649
12/09/2019 Clay B. Siegall
President and CEO; Director
17,327   Disposition at $114.08 per share. 1,976,664
12/09/2019 Clay B. Siegall
President and CEO; Director
500   Derivative/Non-derivative trans. at $12 per share. 6,000
12/09/2019 Clay B. Siegall
President and CEO; Director
1,800   Derivative/Non-derivative trans. at $12 per share. 21,600
12/09/2019 Clay B. Siegall
President and CEO; Director
2,111   Derivative/Non-derivative trans. at $12 per share. 25,332
12/09/2019 Clay B. Siegall
President and CEO; Director
6,734   Derivative/Non-derivative trans. at $12 per share. 80,808
12/09/2019 Clay B. Siegall
President and CEO; Director
17,327   Derivative/Non-derivative trans. at $12 per share. 207,924
12/06/2019 Vaughn B. Himes
Chief Technical Officer
1,049   Disposition at $117.61 per share. 123,372
12/06/2019 Vaughn B. Himes
Chief Technical Officer
6,951   Disposition at $117.09 per share. 813,892
12/06/2019 Vaughn B. Himes
Chief Technical Officer
8,000   Derivative/Non-derivative trans. at $12 per share. 96,000
11/25/2019 Roger D. Dansey
Chief Medical Officer
5,000   Disposition at $121.48 per share. 607,400
11/25/2019 Roger D. Dansey
Chief Medical Officer
5,000   Derivative/Non-derivative trans. at $65.11 per share. 325,550
11/21/2019 Srinivas Akkaraju
Director
4,942   Disposition at $120.46 per share. 595,313
11/21/2019 Srinivas Akkaraju
Director
12,558   Disposition at $119.51 per share. 1,500,806
11/21/2019 Srinivas Akkaraju
Director
4,942   Derivative/Non-derivative trans. at $19.02 per share. 93,996
11/21/2019 Srinivas Akkaraju
Director
12,558   Derivative/Non-derivative trans. at $19.02 per share. 238,853
11/18/2019 Marc E. Lippman
Director
17,500   Disposition at $115.43 per share. 2,020,025
11/18/2019 Marc E. Lippman
Director
17,500   Disposition at $116.17 per share. 2,032,975
11/18/2019 Roger D. Dansey
Chief Medical Officer
5,000   Disposition at $116 per share. 580,000
11/18/2019 Marc E. Lippman
Director
17,500   Derivative/Non-derivative trans. at $12.76 per share. 223,300
11/18/2019 Marc E. Lippman
Director
17,500   Derivative/Non-derivative trans. at $19.02 per share. 332,850
11/18/2019 Roger D. Dansey
Chief Medical Officer
5,000   Derivative/Non-derivative trans. at $65.11 per share. 325,550
11/08/2019 Clay B. Siegall
President and CEO; Director
20,799   Disposition at $108.08 per share. 2,247,955
11/08/2019 Clay B. Siegall
President and CEO; Director
3,968   Disposition at $107.32 per share. 425,845
11/08/2019 Clay B. Siegall
President and CEO; Director
2,120   Disposition at $105.93 per share. 224,571
11/08/2019 Clay B. Siegall
President and CEO; Director
1,585   Disposition at $104.38 per share. 165,442
11/08/2019 Clay B. Siegall
President and CEO; Director
20,799   Derivative/Non-derivative trans. at $12 per share. 249,588
11/08/2019 Clay B. Siegall
President and CEO; Director
3,968   Derivative/Non-derivative trans. at $12 per share. 47,616
11/08/2019 Clay B. Siegall
President and CEO; Director
2,120   Derivative/Non-derivative trans. at $12 per share. 25,440
11/08/2019 Clay B. Siegall
President and CEO; Director
1,585   Derivative/Non-derivative trans. at $12 per share. 19,020
10/08/2019 Clay B. Siegall
President and CEO; Director
14,420   Disposition at $82.01 per share. 1,182,584
10/08/2019 Clay B. Siegall
President and CEO; Director
13,352   Disposition at $82.89 per share. 1,106,747
10/08/2019 Clay B. Siegall
President and CEO; Director
700   Disposition at $83.9 per share. 58,730
10/08/2019 Clay B. Siegall
President and CEO; Director
14,420   Derivative/Non-derivative trans. at $12 per share. 173,040
10/08/2019 Clay B. Siegall
President and CEO; Director
13,352   Derivative/Non-derivative trans. at $12 per share. 160,224
10/08/2019 Clay B. Siegall
President and CEO; Director
700   Derivative/Non-derivative trans. at $12 per share. 8,400
10/01/2019 David W. Gryska
Director
2,500   Disposition at $84.85 per share. 212,125
10/01/2019 David W. Gryska
Director
2,500   Disposition at $85.33 per share. 213,325
10/01/2019 David W. Gryska
Director
2,500   Derivative/Non-derivative trans. at $12.76 per share. 31,900
10/01/2019 David W. Gryska
Director
2,500   Derivative/Non-derivative trans. at $19.02 per share. 47,550
09/30/2019 Todd E. Simpson
Chief Financial Officer
15,000   Disposition at $85 per share. 1,275,000
09/30/2019 Jean I. Liu
GC/EVP, Leg Affairs
3,716   Disposition at $85 per share. 315,860
09/30/2019 Jean I. Liu
GC/EVP, Leg Affairs
3,716   Disposition at $87 per share. 323,292
09/25/2019 Roger D. Dansey
Chief Medical Officer
490   Disposition at $74.24 per share. 36,377
09/25/2019 Roger D. Dansey
Chief Medical Officer
2,510   Disposition at $73.72 per share. 185,037
/news/latest/company/us/sgen

MarketWatch News on SGEN

  1. Seattle Genetics stock up 14% on news of positive trial of breast cancer treatment

    8:39 a.m. Oct. 21, 2019

    - Ciara Linnane

  2. Four stocks that are nearing key breakouts

    2:23 p.m. Oct. 16, 2019

    - Harry Boxer

  3. Charting a shaky October start, S&P 500 challenges key support

    11:49 a.m. Oct. 1, 2019

    - Michael Ashbaugh

  4. Charting a shaky October start, S&P 500 presses key support (2,960)

    11:15 a.m. Oct. 1, 2019

    - Michael Ashbaugh

  5. Atara Biotherapeutics Stock Falls After Goldman Downgrade

    9:50 a.m. Sept. 27, 2019

    - Barron's Online

  6. Seattle Genetics upgraded to outperform from perform at Oppenheimer

    7:37 a.m. Sept. 12, 2019

    - Tomi Kilgore

  7. Seattle Genetics started at hold with $79 stock price target at Deutsche Bank

    1:19 p.m. July 18, 2019

    - Tomi Kilgore

  8. Seattle Genetics started at hold with $70 stock price target at Stifel Nicolaus

    6:28 a.m. April 11, 2019

    - Tomi Kilgore

  9. Seattle Genetics stock price target cut to $92 from $97 at SVB Leerink

    8:29 a.m. Feb. 8, 2019

    - Tomi Kilgore

  10. Immunomedics Chairman Buys $19M More in Stock

    6:19 a.m. June 22, 2018

    - Barron's Online

  11. Engaged Capital Seeks Seats on Aratana Therapeutics Board

    8:08 p.m. May 4, 2018

    - Barron's Online

  12. Seattle Genetics upgraded to overweight from neutral at J.P. Morgan

    8:16 a.m. Feb. 14, 2018

    - Tomi Kilgore

  13. Lattice Semiconductor in Talks With Lion Point Capital

    11:21 p.m. Feb. 9, 2018

    - Barron's Online

  14. Loading more headlines...
/news/nonmarketwatch/company/us/sgen

Other News on SGEN

  1. Seattle Genetics: A Prudent Growth Story

    10:52 a.m. Dec. 11, 2019

    - Seeking Alpha

  2. Cantor likes Aravive in premarket analyst action

    8:55 a.m. Dec. 10, 2019

    - Seeking Alpha

  3. Kinase inhibitors in focus after Merck bid for ArQule

    10:40 a.m. Dec. 9, 2019

    - Seeking Alpha

  4. IBB Is Positioned For Outperformance

    3:43 p.m. Dec. 5, 2019

    - Seeking Alpha

  5. Sell-siders like Tela Bio in premarket analyst action

    8:32 a.m. Dec. 3, 2019

    - Seeking Alpha

  6. Seattle Genetics earns drug approval in Canada

    8:15 a.m. Nov. 25, 2019

    - Seeking Alpha

  7. Healthcare On The March

    12:07 p.m. Nov. 21, 2019

    - Seeking Alpha

  8. Stuff Your IRA With the Best ETFs & Forget About ‘Em

    2:05 p.m. Nov. 18, 2019

    - InvestorPlace.com

  9. 4 RNA Therapy Stocks For A Biotech Portfolio

    2:20 p.m. Nov. 7, 2019

    - Seeking Alpha

  10. Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark

    12:29 p.m. Oct. 30, 2019

    - Zacks.com

  11. Loading more headlines...

At a Glance

Seattle Genetics, Inc.

21823 30th Drive SE

Bothell, Washington 98021

Phone

1 4255274000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2019

Revenue

$654.70M

Net Income

$-222.69M

2018 Sales Growth

35.8%

Employees

1,302

/news/pressrelease/company/us/sgen

Press Releases on SGEN

  1. Annual Changes to the NASDAQ-100 Index

    8:05 p.m. Dec. 13, 2019

    - GlobeNewswire

  2. Annual Changes to the NASDAQ-100 Index

    8:05 p.m. Dec. 13, 2019

    - GlobeNewswire

  3. Loading more headlines...
Link to MarketWatch's Slice.